• Ciprofloxacin is a new quinolone antibiotic that is highly active in vitro against Pseudomonas aeruginosa. A rabbit model of bacterial keratitis was used to assess the in vivo efficacy of topical ciprofloxacin. Albino rabbits received intrastromal injections of 5 × 102 aminoglycoside-resistant P aeruginosa organisms. At five hours after inoculation, ciprofloxacin (3 mg/mL) therapy was initiated (one drop every 30 minutes for 12 hours). Corneal tissue was then excised for bacterial colony counts. No organisms were recovered from ciprofloxacin-treated eyes, compared with an average of 3.1 × 107 organisms per milliliter recovered from untreated controls. This model suggests that topical ciprofloxacin may be clinically useful in the treatment of aminoglycoside-resistant P aeruginosa keratitis.
O'Brien TP, Sawusch MR, Dick JD, Gottsch JD. Topical Ciprofloxacin Treatment of Pseudomonas Keratitis in Rabbits. Arch Ophthalmol. 1988;106(10):1444–1446. doi:10.1001/archopht.1988.01060140608032
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: